NKTR · Nektar Therapeutics

The thesis

Nektar Therapeutics' shares have steadied near $37.97 (adjusted close, 27 October 2026) after falling 62.2% from the 52-week high of $100.35, and the Q3 2026 report (~5 November 2026, est.) is the next event that can change the read. The case rests on $1,023.4 million of cash at 30 June 2026 funding the rezpegaldesleukin Phase 3 programs into the third quarter of 2028, while the market doubts the alopecia durability data shown on 1 October 2026.

The previous note set an invalidation level at a daily close of $42, and that level was broken. The latest close of $37.97 compares with $36.89 on 14 October 2026 and $46.99 on 1 October 2026, the close after the European Academy of Dermatology and Venereology (EADV) data. The three-month price change is -46.9%. The 14-day Relative Strength Index (RSI), a momentum gauge where readings under 30 mark heavy selling, has recovered to 42.3 from 17.2 on 14 October 2026.

Company news since 14 October 2026 shows one item: inducement grants to new employees, announced 25 October 2026. No SEC filings are listed in that period. The narrative is maturing: the data, the Lilly verdict and the analyst initiations are all public, and the only fresh company item since 14 October 2026 is a routine grant notice.

Bullish and bearish views on Nektar Therapeutics

The bull case on Nektar Therapeutics (NKTR), in brief: Cash covers the planned programs. The bear case: The price sits below the cautious targets.

Bull case

• Cash covers the planned programs. Nektar reported $1,023.4 million in cash and investments at 30 June 2026 and guided year-end 2026 cash to $815–840 million (Q2 results, 13 August 2026). The company says that funds operations into the third quarter of 2028, past the mid-2028 atopic-dermatitis Phase 3 readout.
• Phase 3 work has started. Per coverage of the Q2 2026 results, the first atopic-dermatitis Phase 3 trials began in July 2026. A registrational alopecia areata Phase 3 is planned for early 2027.
• A court award adds cash. On 24 September 2026 a jury found Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license and awarded Nektar $90 million plus interest (Nektar release, 25 September 2026). Post-trial motions and an appeal remain possible.
• Several analysts rate the shares far above the price. Leerink Partners initiated at Outperform with a $130 target on 12 October 2026. BTIG reiterated Buy with a $178 target on 9 October 2026, and HC Wainwright reiterated Buy with a $185 target on 2 October 2026.

Bear case

• The price sits below the cautious targets. The close of $37.97 on 27 October 2026 is below UBS's $53 target (Neutral, initiated 12 October 2026) and Wedbush's $50 target (23 September 2026). Raymond James initiated at Market Perform on 9 October 2026.
• Durability rests on eight patients. The sample is too small to support a conclusion about off-treatment response in alopecia areata. Press coverage of the 1 October 2026 data reported 63% of responders holding a hair-loss score (SALT) of 20 or better six months off drug, down from 75% at 52 weeks.
• A weaker cohort did worse. Biotech Distilled reported that a 36-week treatment cohort had 1 of 10 patients responding at six months off drug under a stricter imputation method.
• Revenue is not product income. The roughly $10.1 million quarterly revenue line is legacy royalty and collaboration income. Nektar has no marketed product, so spending draws on cash until the 2029 biologics license application target.
• The rebound has not recovered the data-day loss. The 27 October 2026 close remains below the 1 October 2026 close of $46.99, and press reports put the one-day drop on 1 October 2026 at about 21%.

Price setup

The adjusted daily close was $37.97 on 27 October 2026. That is 62.2% below the 52-week high of $100.35. The shares closed at $36.89 on 14 October 2026, which the previous note called an eight-month low, so the latest close sits just above that low.

The RSI of 42.3 shows the heavy selling of mid-October has eased. The shares trade far below the $46.99 close of 1 October 2026, which is the nearest reference point overhead. A daily close below $32 would extend the slide below the October low and ends the case as written.

Crowding evidence is thin on the buying side. Retail attention spiked on 1 October 2026, when press reports described a one-day fall of about 21%. The Q3 report is about a week away. Nektar's CEO sells shares under a Rule 10b5-1 plan adopted 13 March 2026, so Form 4 filings may be pre-scheduled. No new insider filings are listed since 14 October 2026. Nektar raised $373.8 million net in an April 2026 follow-on offering.

Catalysts, next 30 days

• Later: ~2027-Q1 (est.) alopecia areata Phase 3 start, and ~mid-2028 (est.) initial atopic-dermatitis Phase 3 readout.

Elapsed catalysts

• ~5 November 2026 (est.): Q3 2026 results. Nektar has not announced the date in anything found. The Q3 2025 report came on 6 November 2025 after the close, and the Q2 2026 report on 13 August 2026. The report tests the $815–840 million year-end cash guide and the Q3 2028 funding runway, and it should carry enrollment commentary on the atopic-dermatitis Phase 3. (passed 1d ago)
• Lilly post-trial motions (no date set). The $90 million award of 24 September 2026 is open to motions and appeal. A court order reducing it or a notice of appeal would show in court filings. (passed 43d ago)

What would change the view

The case breaks if Nektar cuts the $815–840 million year-end cash guide or shortens the third-quarter-2028 funding runway at the Q3 report. It also breaks if the alopecia Phase 3 start slips past early 2027, or if a court sets aside the Lilly verdict. On price, a daily close below $32 would end the case as written.

The case strengthens if the Q3 report holds both cash guides and confirms atopic-dermatitis enrollment on schedule. A sustained close above $46.99, the 1 October 2026 post-data close, would show the market has absorbed the alopecia data.

What it trades with

Nektar trades on its own pipeline and legal events more than on sector moves. The 1 October 2026 drop followed Nektar's own data presentation, and the Lilly verdict of 24 September 2026 was a company-specific event. Small and mid-cap immunology developers react to interleukin-2 and dermatology read-throughs from peers, but no peer result has moved the shares in the news reviewed. Funding conditions for pre-revenue biotech also matter, because Nektar's financing history is equity-led.